Pjase I study of peptide vacicination using eitope petide derived from novel oncoantigen for patients with metastatic or recuurent cholangiocarcinoma

Pjase I study of peptide vacicination using eitope petide derived from novel oncoantigen for patients with metastatic or recuurent cholangiocarcinoma - Phase I study of peptide vaccination for patients with cholangiocarcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004660

Enrollment

Registered

2010-12-02

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholangiocarcinoma

Interventions

peptide vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Despite former therapy, Recurrence or being excision impossible cholangiocarcinoma case which desires vaccine therapy. 2) Age between 20 and 85 3) HLA-A*2402 4)Performance status (ECOG) 0 or 1 5)obtains lesion which can be evaluated by RECIST 6)more than 4 weeks after prior therapy 7)without dysfunction of multiple major organs 8) more than 3 months of prognosis 9) obtains written informed consent

Exclusion criteria

Exclusion criteria: 1.severe ischemic heart disease and arrythmia 2. pregnant woman 4. severe active infection disease 5. pateients required administration of steroids 6.multiple cancer patients

Design outcomes

Primary

Measure	Time frame
Evaluation of safety of peptide vaccine and gemcitabine	—

Secondary

Measure	Time frame
Immunological Response, Respoense rate	—

Countries

Japan

Contacts

Public ContactHiroaki Tanaka

Osaka City Osaka CIty University Graduate School Surgical Oncology

hiroakitan@med.osaka-cu.ac.jp06-6645-3838

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026